Table 3.
Study participants
| Participant no. | Race | Age | Annual household income | Cancer type | Treatment location | Years since treatment | Understanding of follow-up | Patient activation | |
|---|---|---|---|---|---|---|---|---|---|
| Group 1, low-activated patients with modest follow-up understandings and limited resources, n = 6 | 6 | Black | 53 | <40,000 | Breast | CH | 6–9 | Limited | Low |
| 11 | Black | 72 | <40,000 | Breast | CH | 10+ | Limited | Low | |
| 13 | Black | 77 | <40,000 | Prostate | CH | 6–9 | Limited | Low | |
| 17 | Black | 75 | 40,000–80,000 | Prostate | CH | 10+ | Limited | Low | |
| 30 | Black | 71 | <40,000 | Breast | CH | 6–9 | Limited | Low | |
| 36 | Black | 64 | 40,000–80,000 | Prostate | CH | <5 | Limited | Low | |
| Group 2, highly activated patients with modest follow-up understandings and moderate resources, n = 12 | 7 | Black | 57 | <40,000 | Breast | CH | 6–9 | Limited | High |
| 8 | White | 62 | 80,000+ | Prostate | CC | <5 | Limited | High | |
| 9 | Black | 73 | <40,000 | Breast | CH | <5 | Limited | High | |
| 12 | Black | 56 | 80,000+ | Breast | CC | 10+ | Limited | High | |
| 16 | Black | 80 | 40,000–80,000 | Prostate | CC | 6–9 | Limited | High | |
| 18 | White | 73 | 40,000–80,000 | Prostate | CH | 10+ | Limited | High | |
| 20 | White | 72 | 80,000+ | Prostate | CH | 6–9 | Limited | High | |
| 26 | White | 73 | 40,000–80,000 | Prostate | CC | 10+ | Limited | High | |
| 31 | Black | 51 | 80,000+ | Breast | CH | 10+ | Limited | High | |
| 40 | White | 63 | 80,000+ | Prostate | CH | 6–9 | Limited | High | |
| 41 | White | 62 | 40,000–80,000 | Prostate | CH | <5 | Limited | High | |
| 42 | White | 72 | 40,000–80,000 | Prostate | CC | 6–9 | Limited | High | |
| Group 3, highly activated patients with detailed follow-up understandings and moderate/high resources, n = 15 | 1 | White | 70 | 40,000–80,000 | Breast | CC | 6–9 | High | High |
| 2 | White | 58 | 80,000+ | Prostate | CC | <5 | High | High | |
| 3 | White | 54 | 80,000+ | Breast | CC | <5 | High | High | |
| 4 | White | 66 | 40,000–80,000 | Breast | CC | <5 | High | High | |
| 10 | White | 70 | 40,000–80,000 | Breast | CC | 10+ | High | High | |
| 14 | White | 65 | 80,000+ | Breast | CH | <5 | High | High | |
| 15 | White | 59 | 80,000+ | Prostate | CC | <5 | High | High | |
| 19 | White | 70 | 80,000+ | Prostate | CH | <5 | High | High | |
| 24 | White | 59 | 80,000+ | Prostate | CC | <5 | High | High | |
| 28 | White | 47 | 80,000+ | Breast | CC | 10+ | High | High | |
| 29 | White | 79 | 40,000–80,000 | Prostate | CC | 10+ | High | High | |
| 32 | White | 56 | 80,000+ | Breast | CH | 6–9 | High | High | |
| 33 | White | 49 | 80,000+ | Breast | CH | 10+ | High | High | |
| 35 | White | 60 | 40,000–80,000 | Breast | CH | <5 | High | High | |
| 43 | White | 60 | 80,000+ | Prostate | CC | 6–9 | High | High |
CC cancer center, CH community hospital